ARVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arvinas Inc (ARVN) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks immediate positive catalysts, has weak financial performance, and no proprietary trading signals. While analysts have raised price targets and maintain positive ratings, the company's recent financials and lack of significant trading trends suggest a cautious approach.
The MACD histogram is slightly positive at 0.0178, indicating mild bullish momentum, but it is contracting. RSI is at 28.48, in the neutral zone, and moving averages are converging, showing no clear trend. The stock is trading near its key support level of 10.411, with resistance at 11.206.
Analysts have raised price targets and maintain Buy or Overweight ratings, citing progress in clinical trials and a strong cash position to fund operations into 2028.
Net income is still negative, and the stock lacks recent news or significant trading trends. Congress trading data and proprietary trading signals are absent.
In Q4 2025, revenue dropped to $9.5M (-83.95% YoY). However, net income improved to -$67.4M (+49.45% YoY), and EPS increased to -1.04 (+65.08% YoY). Gross margin remained stable at 100%.
Analysts have raised price targets recently, with Citi increasing it to $21 and Piper Sandler to $20. Positive Phase 1 data and upcoming clinical trials are driving optimism, but some analysts remain neutral pending further clinical insights.
